Orientation and Cellular Distribution of Membrane-bound Catechol-O-methyltransferase in Cortical Neurons IMPLICATIONS FOR DRUG DEVELOPMENT

被引:59
作者
Chen, Jingshan [1 ]
Song, Jian [1 ]
Yuan, Peixiong [1 ]
Tian, Qingjun [1 ]
Ji, Yuanyuan [1 ]
Ren-Patterson, Renee [1 ]
Liu, Guangping [1 ]
Sei, Yoshitasu [1 ]
Weinberger, Daniel R. [1 ]
机构
[1] NIMH, Clin Brain Disorders Branch, Genes Cognit & Psychosis Program, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
MESSENGER-RNA; PROTEIN EXPRESSION; DOPAMINE CLEARANCE; PREFRONTAL CORTEX; GENETIC-VARIATION; ENZYME-ACTIVITY; RAT-BRAIN; COMT; LIVER; INHIBITORS;
D O I
10.1074/jbc.M111.262790
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Catechol-O-methyltransferase (COMT) is a key enzyme for inactivation and metabolism of catechols, including dopamine, norepinephrine, caffeine, and estrogens. It plays an important role in cognition, arousal, pain sensitivity, and stress reactivity in humans and in animal models. The human COMT gene is associated with a diverse spectrum of human behaviors and diseases from cognition and psychiatric disorders to chronic pain and cancer. There are two major forms of COMT proteins, membrane-bound (MB) COMT and soluble (S) COMT. MB-COMT is the main form in the brain. The cellular distribution of MB-COMT in cortical neurons remains unclear and the orientation of MB-COMT on the cellular membrane is controversial. In this study, we demonstrate that MB-COMT is located in the cell body and in axons and dendrites of rat cortical neurons. Analyses of MB-COMT orientation with computer simulation, flow cytometry and a cell surface enzyme assay reveal that the C-terminal catalytic domain of MB-COMT is in the extracellular space, which suggests that MB-COMT can inactivate synaptic and extrasynaptic dopamine on the surface of presynaptic and postsynaptic neurons. Finally, we show that the COMT inhibitor tolcapone induces cell death via the mechanism of apoptosis, and its cytotoxicity is dependent on dosage and correlated with COMT Val/Met genotypes in human lymphoblastoid cells. These results suggest that MB-COMT specific inhibitors can be developed and that tolcapone may be less hazardous at low doses and in specific genetic backgrounds.
引用
收藏
页码:34752 / 34760
页数:9
相关论文
共 44 条
[1]   Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity [J].
Acuña G. ;
Foernzler D. ;
Leong D. ;
Rabbia M. ;
Smit R. ;
Dorflinger E. ;
Gasser R. ;
Hoh J. ;
Ott J. ;
Borroni E. ;
To Z. ;
Thompson A. ;
Li J. ;
Hashimoto L. ;
Lindpaintner K. .
The Pharmacogenomics Journal, 2002, 2 (5) :327-334
[2]  
Akil M, 2003, J NEUROSCI, V23, P2008
[3]   Tolcapone improves cognition and cortical information processing in normal human subjects [J].
Apud, Jose A. ;
Mattay, Venkata ;
Chen, Jingshan ;
Kolachana, Bhaskar S. ;
Callicott, Joseph H. ;
Rasetti, Roberta ;
Alce, Guilna ;
Iudicello, Jennifer E. ;
Akbar, Natkai ;
Egan, Michael F. ;
Goldberg, Terry E. ;
Weinberger, Daniel R. .
NEUROPSYCHOPHARMACOLOGY, 2007, 32 (05) :1011-1020
[4]   Functional analysis of genetic variation in catechol-o-methyltransferase (COMT):: Effects on mRNA, protein, and enzyme activity in postmortem human brain [J].
Chen, JS ;
Lipska, BK ;
Halim, N ;
Ma, QD ;
Matsumoto, M ;
Melhem, S ;
Kolachana, BS ;
Hyde, TM ;
Herman, MM ;
Apud, J ;
Egan, MF ;
Kleinman, JE ;
Weinberger, DR .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (05) :807-821
[5]  
Davies NM, 2004, J PHARM PHARM SCI, V7, P332
[6]   INTEGRATED PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL CATECHOL-O-METHYLTRANSFERASE INHIBITOR TOLCAPONE DURING FIRST ADMINISTRATION TO HUMANS [J].
DINGEMANSE, J ;
JORGA, KM ;
SCHMITT, M ;
GIESCHKE, R ;
FOTTELER, B ;
ZURCHER, G ;
DAPRADA, M ;
VANBRUMMELEN, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (05) :508-517
[7]   Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia [J].
Egan, MF ;
Goldberg, TE ;
Kolachana, BS ;
Callicott, JH ;
Mazzanti, CM ;
Straub, RE ;
Goldman, D ;
Weinberger, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (12) :6917-6922
[8]   Statins and myotoxicity [J].
John A. Farmer .
Current Atherosclerosis Reports, 2003, 5 (2) :96-100
[9]   Prefrontal and striatal dopaminergic genes predict individual differences in exploration and exploitation [J].
Frank, Michael J. ;
Doll, Bradley B. ;
Oas-Terpstra, Jen ;
Moreno, Francisco .
NATURE NEUROSCIENCE, 2009, 12 (08) :1062-U145
[10]  
Goetz Christopher G., 1998, Neurology, V50, pS26